From: Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte
DM patients | Non-DM patients | P | |
---|---|---|---|
N | 47 | 93 | / |
Mean age (years) | 52.9±6.7 | 53.7±4.1 | 0.19 |
Sex, male (%) | 35 (74) | 73 (78) | 0.36 |
BMI (kg/m2) | 27.3±1.2 | 25.7±1.6 | 0.001 |
Aetiology of heart failure, n (%) | |||
Ischemic cardiomyopathy | 25 (53) | 50 (54) | 0.54 |
Dilated cardiomyopathy | 20 (42) | 37 (40) | 0.27 |
Other | 2 (4) | 6 (6) | 0.33 |
Cardiovascular risk factors, n (%) | |||
Hypertension, n (%) | 12 (25) | 25 (27) | 0.52 |
Dyslipidemia, n (%) | 21 (45) | 30 (32) | 0.10 |
Family history of CAD, n (%) | 27 (57) | 45 (48) | 0.20 |
Smoking history, n (%) | 5 (11) | 10 (11) | 0.61 |
Laboratory analyses | |||
Plasma glucose (mg/dl) | 126.7±18.7 | 88.7±6.7 | 0.001 |
HbA1c (%) | 6.7±1.2 | 4.8±0.8 | 0.007 |
Cholesterol (mg/dl) | 177.1±21.6 | 161.7±18.7 | 0.011 |
LDL-cholesterol (mg/dl) | 101.1±22.7 | 97.4±16.7 | 0.16 |
HDL-cholesterol (mg/dl) | 40.9±1.1 | 41.8±1.7 | 0.21 |
Triglycerides (mg/dl) | 172.4±28.2 | 113.4±11.1 | 0.013 |
Creatinine (mg/dl) | 1.0±0.37 | 1.0±0.26 | 0.74 |
Therapy | |||
ACEi, n (%) | 40 (85) | 83 (89) | 0.33 |
ARBs, n (%) | 15 (32) | 34 (37) | 0.36 |
Diuretic, n (%) | 45 (96) | 92 (99) | 0.26 |
Antiaggregant, n (%) | 46 (98) | 83 (89) | 0.06 |
Anticoagulant, n (%) | 5 (11) | 16 (17) | 0.22 |
Statin, n (%) | 40 (85) | 70 (75) | 0.12 |
Beta-blockers, n (%) | 47 (100) | 90 (97) | 0.55 |
Sacubitril-valsartan, n (%) | 21 (45) | 31 (33) | 0.13 |
Nitrate, n (%) | 21 (45) | 37 (40) | 0.35 |
Calcium-antagonist, n (%) | 7 (15) | 6 (6) | 0.96 |